DOJ and SEC Issue Long-Awaited FCPA Guidance
Client Alert | 1 min read | 11.14.12
The Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) today issued long-awaited written guidance on the U.S. Foreign Corrupt Practices Act (FCPA), in a 120-page publication entitled A Resource Guide to the U.S. Foreign Corrupt Practices Act. According to the government, the Guide aims to "provide helpful information to enterprises of all shapes and sizes – from small businesses doing their first transactions abroad to multi-national corporations with subsidiaries around the world."
The Guide covers numerous topics, including several that are at the forefront of compliance officers' minds and central to current litigation, enforcement actions, and negotiations. Topics the Guide addresses include:
- Who and what are covered by the FCPA's bribery and accounting provisions
- What are proper and improper gifts, travel, and entertainment expenses
- The definition of "foreign official"
- The scope of the facilitating payments exception
- The affirmative defenses, such as reimbursement of reasonable travel expenses
- How successor liability applies in the M&A context
- The hallmarks of effective corporate compliance programs
- Penalties, sanctions, and remedies
- Available types of criminal and civil resolution
The Guide reflects not only the government's interpretation of the law, but also its enforcement practices, providing hypotheticals and examples of enforcement actions and declinations. The Guide also includes discussion of the impact of self-reporting, cooperation, corporate compliance programs and remedial efforts.
Understanding the Guide, which may be found here, will be essential to any company that could fall within the broad reach of the FCPA. To that end, we will issue a full analysis within the next few days.
Contacts
Insights
Client Alert | 5 min read | 10.22.26
CMS Proposes Major Changes to MA, Part D, and PBM Requirements
On October 16, 2026, the U.S. Centers for Medicare and Medicaid Services (CMS) issued a proposed rule implementing key sections of the Consolidated Appropriations Act (CAA) of 2026, Section 6224 (“Modernizing and Ensuring Pharmacy Benefit Manager Accountability”). The agency also proposes a conforming change mandated by section 6219 of the CAA (“Adjustments to Medicare Part D Cost-Sharing Reductions for Low-Income Individuals”) that would reduce the generic-drug copayment from $1 to $0 for full-benefit dual eligible individuals. Comments to the proposed rule are due December 15, 2026.
Client Alert | 4 min read | 10.22.26
When the Clock Strikes Twice: Crocs Takes Piecemeal ITC Appeals to the Supreme Court
Client Alert | 9 min read | 10.21.26
Client Alert | 2 min read | 10.21.26



